Category Specific RSS

LOX inhibitor

Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer…

2 years ago